New long-standing metabolites of 17α-methyltestosterone are detected in HepG2 cell in vitro metabolic model and in human urine.
17α-methyltestosterone
HepG2
anabolic androgenic steroids
doping control
in vitro metabolism
Journal
Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449
Informations de publication
Date de publication:
30 Oct 2023
30 Oct 2023
Historique:
revised:
17
08
2023
received:
15
06
2023
accepted:
08
10
2023
medline:
31
10
2023
pubmed:
31
10
2023
entrez:
30
10
2023
Statut:
aheadofprint
Résumé
Novel metabolites of the anabolic androgenic steroid 17α-methyltestosterone have been detected in HepG2 cell in vitro metabolic model and in human urine. Their detection was accomplished through targeted gas chromatography-(tandem) mass spectrometry analysis that has been based on microscale synthesized standards. The related synthesis and the gas chromatography-(tandem) mass spectrometry characterization of the analytical standards are described. All newly presented metabolites have a fully reduced steroid A-ring with either an 17,17-dimethyl-18-nor-Δ13 structure or they have been further oxidized at position 16 of the steroid backbone. Metabolites with 17,17-dimethyl-18-nor-Δ13 structure may be considered as side products of phase II metabolic sulfation of the 17β-hydroxy group of methyltestosterone or its reduced tetrahydro-methyltestosterone metabolites 17α-methyl-5β-androstane-3α,17β-diol and 17α-methyl-5α-androstane-3α,17β-diol that produce the known epimeric 17β-methyl-5β-androstane-3α,17α-diol and 17β-methyl-5α-androstane-3α,17α-diol metabolites. The prospective of these new metabolites to increase detection time windows and improve identification was investigated by applying the World Anti-doping Agency TD2021IDCR criteria. The new metabolites, presented herein, complement the current knowledge on the 17α-methyltestosterone metabolism and in some cases can be used as additional long-term markers in the frame of sport doping drug testing.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. Drug Testing and Analysis published by John Wiley & Sons Ltd.
Références
World Anti-Doping Agency. 2021 anti-doping testing figures. Accessed March 26, 2023. https://www.wada-ama.org/sites/default/files/2023-01/2021_antidoping_testing_figures_en.pdf
Walpurgis K, Piper T, Thevis M. Androgens, sports, and detection strategies for anabolic drug use. Best Pract Res Clin Endocrinol Metab. 2022;36(4):101609. doi:10.1016/j.beem.2021.101609
Schänzer W, Donike M. Metabolism of anabolic steroids in man: synthesis and use of reference substances for identification of anabolic steroid metabolites. Anal Chim Acta. 1993;275(1-2):23-48. doi:10.1016/0003-2670(93)80274-O
Schänzer W. Metabolism of anabolic androgenic steroids. Clin Chem. 1996;42(7):1001-1020. doi:10.1093/clinchem/42.7.1001
Van Eenoo P, Delbeke FT. Metabolism and excretion of anabolic steroids in doping control-new steroids and new insights. J Steroid Biochem Mol Biol. 2006;101(4-5):161-178. doi:10.1016/j.jsbmb.2006.06.024
Fragkaki AG, Angelis YS, Tsantili-Kakoulidou A, Koupparis M, Georgakopoulos C. Schemes of metabolic patterns of anabolic androgenic steroids for the estimation of metabolites of designer steroids in human urine. J Steroid Biochem Mol Biol. 2009;115(1-2):44-61. doi:10.1016/j.jsbmb.2009.02.016
Stojanovic BJ, Göschl L, Forsdahl G, Günter G. Metabolism of steroids and sport drug testing. Bioanalysis. 2020;12(9):561-563. doi:10.4155/bio-2020-0077
Fitzgerald CCJ, Bowen C, Elbourne M, Cawley A, McLeod MD. Energy-resolved fragmentation aiding the structure elucidation of steroid biomarkers. J am Soc Mass Spectrom. 2022;33(7):1276-1281. doi:10.1021/jasms.2c00092
Velosa DC, Dunham AJ, Rivera ME, Neal SP, Chouinard CD. Improved ion mobility separation and structural characterization of steroids using derivatization methods. J am Soc Mass Spectrom. 2022;33(9):1761-1771. doi:10.1021/jasms.2c00164
Bressan C, Celma A, Alechaga É, Monfort N, Ventura R, Sancho JV. Effects of structural characteristics of (un)conjugated steroid metabolites in their collision cross section value. Anal Chim Acta. 2023;1254:341128. doi:10.1016/j.aca.2023.341128
Albertsdóttir AD, Van Gansbeke W, Van Eenoo P, Polet M. Detection time comparison of non-hydrolysed sulphated metabolites of metenolone, mesterolone and 17α-methyltestosterone analysed by four different mass spectrometric techniques. Drug Test Anal. 2023;15(8):853-864. doi:10.1002/dta.3481
Polet M, Van Gansbeke W, Geldof L, Deventer K, Van Eenoo P. Identification and characterization of novel long-term metabolites of oxymesterone and mesterolone in human urine by application of selected reaction monitoring GC-CI-MS/MS. Drug Test Anal. 2017;9(11-12):1673-1684. doi:10.1002/dta.2183
Lu J, Fernández-Álvarez M, Yang S, He G, Xu Y, Aguilera R. New potential biomarkers for mesterolone misuse in human urine by liquid chromatography quadrupole time-of-flight mass spectrometry. J Mass Spectrom. 2015;50(1):153-159. doi:10.1002/jms.3508
Kiousi P, Angelis YS, Fragkaki AG, et al. Markers of mesterolone abuse in sulfate fraction for doping control in human urine. J Mass Spectrom. 2015;50(12):1409-1419. doi:10.1002/jms.3715
Albertsdóttir AD, Van Gansbeke W, Van Eenoo P, Polet M. Evaluation of alternative gas chromatographic and mass spectrometric behaviour of trimethylsilyl-derivatives of non-hydrolysed sulfated anabolic steroids. Drug Test Anal. 2023. doi:10.1002/dta.3462
Angelis YS, Fragkaki AG, Kiousi P, Sakellariou P, Christophoridis C. LC-MS/(MS) confirmatory doping control analysis of intact phase II metabolites of methenolone and mesterolone after Girard's Reagent T derivatization. Drug Test Anal. 2023;15(6):654-667. doi:10.1002/dta.3465
Schänzer W, Guddat S, Thomas A, Opfermann G, Geyer H, Thevis M. Expanding analytical possibilities concerning the detection of stanozolol misuse by means of high resolution/high accuracy mass spectrometric detection of stanozolol glucuronides in human sports drug testing. Drug Test Anal. 2013;5(11-12):810-818. doi:10.1002/dta.1516
Tudela E, Deventer K, Van Eenoo P. Sensitive detection of 3′-hydroxy-stanozolol glucuronide by liquid chromatography-tandem mass spectrometry. J Chromatogr A. 2013;1292:195-200. doi:10.1016/j.chroma.2013.01.001
Göschl L, Gmeiner G, Gärtner P, et al. Stanozolol-N-glucuronide metabolites in human urine samples as suitable targets in terms of routine anti-doping analysis. Drug Test Anal. 2021;13(9):1668-1677. doi:10.1002/dta.3109
Fragkaki AG, Angelis YS, Kiousi P, Georgakopoulos CG, Lyris E. Comparison of sulfo-conjugated and gluco-conjugated urinary metabolites for detection of methenolone misuse in doping control by LC-HRMS, GC-MS and GC-HRMS. J Mass Spectrom. 2015;50(5):740-748. doi:10.1002/jms.3583
He G, Yang S, Lu J, Xu Y. New long term metabolite in human urine for metenolone misuse by liquid chromatography quadrupole time-of-flight mass spectrometry. Steroids. 2016;105:1-11. doi:10.1016/j.steroids.2015.10.015
Albertsdóttir AD, Van Gansbeke W, Coppieters G, et al. Searching for new long-term urinary metabolites of metenolone and drostanolone using gas chromatography-mass spectrometry with a focus on non-hydrolysed sulfates. Drug Test Anal. 2020;12(8):1041-1053. doi:10.1002/dta.2818
Liu Y, Lu J, Yang S, Zhang Q, Xu Y. New drostanolone metabolites in human urine by liquid chromatography time-of-flight tandem mass spectrometry and their application for doping control. Steroids. 2016;108:61-67. doi:10.1016/j.steroids.2016.01.013
Schänzer W, Geyer H, Fusshöller G, et al. Mass spectrometric identification and characterization of a new long-term metabolite of metandienone in human urine. Rapid Commun Mass Spectrom. 2006;20(15):2252-2258. doi:10.1002/rcm.2587
Gómez C, Pozo OJ, Garrostas L, Segura J, Ventura R. A new sulphate metabolite as a long-term marker of metandienone misuse. Steroids. 2013;78(12-13):1245-1253. doi:10.1016/j.steroids.2013.09.005
Sobolevsky T, Rodchenkov G. Detection and mass spectrometric characterization of novel long-term dehydrochloromethyltestosterone metabolites in human urine. J Steroid Biochem Mol Biol. 2012;128(3-5):121-127. doi:10.1016/j.jsbmb.2011.11.004
Göschl L, Gmeiner G, Gärtner P, Steinacher M, Forsdahl G. Detection of DHCMT long-term metabolite glucuronides with LC-MSMS as an alternative approach to conventional GC-MSMS analysis. Steroids. 2022;180:108979. doi:10.1016/j.steroids.2022.108979
Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther. 2001;23(9):1355-1390. doi:10.1016/s0149-2918(01)80114-4
Fragkaki AG, Angelis YS, Koupparis M, Tsantili-Kakoulidou A, Kokotos G, Georgakopoulos C. Structural characteristics of anabolic androgenic steroids contributing to binding to the androgen receptor and to their anabolic and androgenic activities. Applied modifications in the steroidal structure. Steroids. 2009;74(2):172-197. doi:10.1016/j.steroids.2008.10.016
Pozo OJ, Van Eenoo P, Deventer K, et al. Detection and characterization of a new metabolite of 17alpha-methyltestosterone. Drug Metab Dispos. 2009;37(11):2153-2162. doi:10.1124/dmd.109.028373
Gómez C, Pozo OJ, Marcos J, Segura J, Ventura R. Alternative long-term markers for the detection of methyltestosterone misuse. Steroids. 2013;78(1):44-52. doi:10.1016/j.steroids.2012.10.008
Martinez-Brito D, Iannone M, Tatangelo MA, Molaioni F, de la Torre X, Botre F. A further insight into methyltestosterone metabolism: new evidences from in vitro and in vivo experiments. Rapid Commun Mass Specrtrom. 2020;34(19):e8870. doi:10.1002/rcm.8870
Loke S, Liu L, Wenzel M, et al. New insights into the metabolism of methyltestosterone and metandienone: detection of novel A-ring reduced metabolites. Molecules. 2021;26(5):1354. doi:10.3390/molecules26051354
Schänzer W, Opfermann G, Donike M. 17-Epimerization of 17 alpha-methyl anabolic steroids in humans: metabolism and synthesis of 17 alpha-hydroxy-17 beta-methyl steroids. Steroids. 1992;57(11):537-550. doi:10.1016/0039-128x(92)90023-3
McKinney AR, Suann CJ, Stenhouse AM. A stereochemical examination of the equine metabolism of 17alpha-methyltestosterone. Anal Chim Acta. 2007;581(2):377-387. doi:10.1016/j.aca.2006.08.025
Yamada M, Aramaki S, Okayasu T, et al. Identification and quantification of metabolites common to 17alpha-methyltestosterone and mestanolone in horse urine. J Pharm Biomed Anal. 2007;45(1):125-133. doi:10.1016/j.jpba.2007.06.020
Schänzer W, Delahaut P, Geyer H, Machnik M, Horning S. Long-term detection and identification of metandienone and stanozolol abuse in athletes by gas chromatography-high-resolution mass spectrometry. J Chromatogr B Biomed Appl. 1996;687(1):93-108. doi:10.1016/s0378-4347(96)00187-9
Granata OM, Cocciadiferro L, Miceli V, Polito LM, Campisi I, Carruba G. Metabolic profiles of androgens in malignant human liver cell lines. Ann N Y Acad Sci. 2006;1089(1):262-267. doi:10.1196/annals.1386.028
Gomez-Lechon M, Donato M, Lahoz A, Castell J. Cell lines: a tool for in vitro drug metabolism studies. Curr Drug Metab. 2008;9(1):1-11. doi:10.2174/138920008783331086
Zschiesche A, Chundela Z, Thieme D, Keiler AM. HepG2 as promising cell-based model for biosynthesis of long-term metabolites: exemplified for metandienone. Drug Test Anal. 2022;14(2):298-306. doi:10.1002/dta.3184
Gronert A, Zierau O, Thieme D, Keiler AM. Effect of HepG2 cell 3D cultivation on the metabolism of the anabolic androgenic steroid metandienone. Drug Test Anal. 2023. doi:10.1002/dta.3455
Savill R, Baues H, Voigt E, Zierau O, Thieme D, Keiler AM. Cell culture as a toolbox to generate phase I metabolites for antidoping screening. Drug Test Anal. 2021;13(6):1169-1177. doi:10.1002/dta.3009
Parr MK, Zapp J, Becker M, Opfermann G, Bartz U, Schänzer W. Steroidal isomers with uniform mass spectra of their per-TMS derivatives: synthesis of 17-hydroxyandrostan-3-ones, androst-1-, and -4-ene-3,17-diols. Steroids. 2007;72(6-7):545-551. doi:10.1016/j.steroids.2007.03.006
Parr MK, Blatt C, Zierau O, et al. Endocrine characterization of the designer steroid methyl-1-testosterone: investigations on tissue-specific anabolic-androgenic potency, side effects, and metabolism. Endocrinology. 2011;152(12):4718-4728. doi:10.1210/en.2011-1164
World Anti-Doping Agency. TD2021IDCR. Accessed May 23, 2023. https://www.wada-ama.org/sites/default/files/resources/files/td2021idcr_final_eng_0.pdf